Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Common Equity: 2013-2024

Historic Common Equity for KalVista Pharmaceuticals (KALV) over the last 9 years, with Apr 2024 value amounting to $206.6 million.

  • KalVista Pharmaceuticals' Common Equity was N/A to $164.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $164.4 million, marking a year-over-year change of. This contributed to the annual value of $206.6 million for FY2024, which is N/A change from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Common Equity stood at $206.6 million for FY2024, which was up 146.66% from $83.8 million recorded in FY2020.
  • Over the past 5 years, KalVista Pharmaceuticals' Common Equity peaked at $206.6 million during FY2024, and registered a low of $83.8 million during FY2020.
  • In the last 1 years, KalVista Pharmaceuticals' Common Equity had a median value of $206.6 million in 2024 and averaged $206.6 million.
  • Data for KalVista Pharmaceuticals' Common Equity shows a maximum YoY fell of 13.42% (in 2020) over the last 5 years.
  • KalVista Pharmaceuticals' Common Equity (Yearly) stood at $83.8 million in 2020, then followed by $206.6 million in 2024.